ABBV vs RGNX

AbbVie Inc. (ABBV) is a well-established mega-cap pharmaceutical company with a robust product portfolio, strong financial health, and a leading position in key therapeutic areas. It excels as a stable dividend payer and a defensive holding. However, its fundamental characteristics, including its immense market capitalization ($397.29B), the mature nature of the pharmaceutical industry, high R&D c...

Regenxbio faces a significantly elevated risk profile since the last analysis. While its proprietary NAV gene therapy platform and the lead asset RGX-314 (wet AMD) with the AbbVie partnership still offer multi-billion dollar market potential, recent events have introduced substantial uncertainty. The FDA clinical holds on two key pipeline assets (RGX-111 and RGX-121), including a neoplasm case, ra...